Jun 27, 2019   SOURCE: PR NewsWire

CB-839 (Calithera Biosciences) Drug Overview 2019: CB-839 will be the First Glutaminase Inhibitor Approved for the Treatment of Renal Cell Carcinoma

DUBLIN, June 27, 2019 /PRNewswire/ -- The "CB-839" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cancer cells are known to rely on glycolysis as an energy source. CB-839 (Calithera Biosciences) inhibits the glutaminase enzyme, reducing the ability of cancer cells to utilize glutamine in this biochemical pathway, thereby reducing cell proliferation and tumor growth.

If approved, CB-839 will be the first glutaminase inhibitor approved for the treatment of renal cell carcinoma (RCC). This novel mechanism of action could place CB-839 in a unique position in the RCC market and provide physicians with an alternative treatment option.

CB-839 is being investigated in combination with either Afinitor (everolimus; Novartis) or Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) for previously treated advanced RCC patients, suggesting it will not compete with the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) therapies being developed for first-line use.

CB-839 is being developed by Calithera Biosciences, a company that is yet to bring an oncology product to market. Due to Calithera's limited geographic scope, the author expects the company to look for partners to market CB-839 in Japan and the EU.

Key Topics Covered:

OVERVIEW

    --  Drug Overview
    --  Product Profiles
    --  CB-839 : Renal cell carcinoma (RCC)

LIST OF FIGURES

    --  CB-839 for RCC - SWOT analysis
    --  The authors drug assessment summary of CB-839 for RCC
    --  CB-839 sales for RCC in the US, 2017-26

LIST OF TABLES

    --  CB-839 drug profile
    --  CB-839 Phase II trials in RCC
    --  CB-839 sales for RCC in the US ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/r/3u15na

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/cb-839-calithera-biosciences-drug-overview-2019-cb-839-will-be-the-first-glutaminase-inhibitor-approved-for-the-treatment-of-renal-cell-carcinoma-300875360.html

SOURCE Research and Markets